SCHEMBL6498091

SCHEMBL6498091

Cc1cccc(CNc2ccc3oc4ccccc4c3c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.44
KDM4E B2RXH2 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
HPGD P15428 3/20 0.44
MEN1 O00255 3/20 0.44
ALOX15 P16050 2/20 0.44
GAA P10253 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CXCR4 P61073 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
MAP3K8 P41279 1/20 0.39
HDAC6 Q9UBN7 1/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483367 0.88 BRD4 (0.43) RAB9AKMT2AALDH1A1HPGDMEN1
SCHEMBL6482209 0.80 KDM4E (0.61) RAB9AKDM4EKMT2AALDH1A1MAPT
SCHEMBL6496815 0.80 RAB9A (0.39) RAB9AKDM4EKMT2AALDH1A1MAPT
SCHEMBL6483310 0.76 MAOB (0.46) KDM4EKMT2AALDH1A1MAPTHPGD
SCHEMBL6481920 0.76 EGFR (0.50) RAB9AKDM4EKMT2AALDH1A1MAPT
SCHEMBL6481670 0.76 MAOB (0.46) RAB9AKDM4EKMT2AALDH1A1MAPT
SCHEMBL6493319 0.76 HTT (0.53) RAB9AKDM4EKMT2AALDH1A1MAPT
SCHEMBL7246584 0.75 CYP1A2 (0.53) RAB9AKDM4EKMT2AALDH1A1MAPT
SCHEMBL6482295 0.75 HPGD (0.54) RAB9AKDM4EKMT2AALDH1A1MAPT
SCHEMBL6492990 0.74 RXFP1 (0.44) KDM4EKMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 RAB9A 4535/4885KDM4E 1279/4885KMT2A 412/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 RAB9A 3961/4885KDM4E 1476/4885KMT2A 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.